Browsing Tag
JNJ
2 posts
JNJ’s pasritamig plus docetaxel advances to Phase 3 after strong early results in metastatic castration-resistant prostate cancer
Johnson & Johnson's pasritamig hits 75% PSA response in taxane-naive prostate cancer patients. What Phase 3 means for JNJ's oncology strategy. Read more.
Johnson & Johnson announces $13.1bn acquisition of Shockwave Medical to strengthen medtech division
In a monumental move within the medical technology sector, Johnson & Johnson (NYSE: JNJ) has announced its acquisition…